Kodiak Sciences Inc Common Stock KOD
Analyst Ratings
- Consensus
- Buy — 5 Buy · 1 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $87.33 (-2.9% downside)
Key Stats
- Today's Range
- $60.49 – $95.77
- 50-Day Range
- $29.81 – $95.77
- 52-Week Range
- $8.29 – $95.77
- Volume
- 38.56 million shs
- Average Volume
- 2.02 million shs
- Market Cap
- $2.03 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
About Kodiak Sciences Inc Common Stock
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Related Stocks
Compare head-to-head: KOD vs AMGN·KOD vs MRNA·KOD vs HALO·KOD vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.